Literature DB >> 7805841

Cloning and characterization of the human V3 pituitary vasopressin receptor.

Y de Keyzer1, C Auzan, F Lenne, C Beldjord, M Thibonnier, X Bertagna, E Clauser.   

Abstract

Arginine-vasopressin (AVP) plays a determinant role in the normal ACTH response to stress in mammals. We cloned a human cDNA coding a 424 amino acid G-protein coupled receptor structurally related to the vasopressin/oxytocin receptor family. When expressed in COS cells, this receptor binds AVP with a high affinity (Kd = 0.55 +/- 0.13 nM) and is functionally coupled to phospholipase C. Competition studies with peptidic or non peptidic AVP analogues reveal that it is pharmacologically distinct from V1a and V2 AVP receptors and therefore it is designated V3. RT-PCR analysis shows that the human V3 receptor is expressed in normal pituitary and also in kidney, but is undetectable in liver, myometrium and adrenal gland. Northern blot analysis reveals a approximately 4.8 kb messenger in human corticotropic pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805841     DOI: 10.1016/0014-5793(94)01268-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.

Authors:  S Nakamura; Y Yamamura; S Itoh; T Hirano; K Tsujimae; M Aoyama; K Kondo; H Ogawa; T Shinohara; K Kan; Y Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; T Mori; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 2.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

3.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

4.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

5.  Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Authors:  Sylvia Chen; Matthew J Webber; Jean-Pierre Vilardaga; Ashok Khatri; Dennis Brown; Dennis A Ausiello; Herbert Y Lin; Richard Bouley
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

6.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

7.  Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei.

Authors:  Jia-Da Li; Katherine J Burton; Chengkang Zhang; Shuang-Bao Hu; Qun-Yong Zhou
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-03       Impact factor: 3.619

8.  The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.

Authors:  Akito Tanoue; Shuji Ito; Kenji Honda; Sayuri Oshikawa; Yoko Kitagawa; Taka-Aki Koshimizu; Toyoki Mori; Gozoh Tsujimoto
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 9.  Two types of ectopic Cushing syndrome or a continuum? Review.

Authors:  Marta Araujo Castro; Mónica Marazuela Azpiroz
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

10.  Molecular modeling of the human vasopressin V2 receptor/agonist complex.

Authors:  C Czaplewski; R Kaźmierkiewicz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  1998-05       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.